RxDoctor Payments Data

Samar Sheth, MD

Cardiovascular Disease · Houston, TXNPI 1013146901

Payments from drug & device makers

$248,691in general payments, 2019–2025

Across 771 payments — averaging $322.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$148K
  • Siemens Medical Solutions USA, Inc.$77K
  • Abiomed$4K
  • Abbott$4K
  • Medtronic$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • plus $12K from 52 others
$224in research payments, 2019–2025

Across 2 payments — averaging $112.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$224

What the payments were for

  • Travel & lodging$1,9248%
  • Food & beverage$23,63192%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$248,691 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$776,263
Medicare patients
812
Services billed
5,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$268,313
EntrestoSacubitril/Valsartan91$129,544
XareltoRivaroxaban83$113,017
Repatha SureclickEvolocumab82$87,668
JardianceEmpagliflozin95$86,155
FarxigaDapagliflozin Propanediol54$56,641
OzempicSemaglutide47$56,556
MounjaroTirzepatide24$28,547
NexlizetBempedoic Acid/Ezetimibe16$16,628
MultaqDronedarone Hcl14$10,151
NexletolBempedoic Acid11$6,785
Metoprolol Succinate326$5,808
Atorvastatin Calcium307$3,600
ClopidogrelClopidogrel Bisulfate188$2,915
Rosuvastatin Calcium213$2,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$587$268,313229 claims
NovartisEntresto$147,624$129,54491 claims
Johnson & JohnsonXarelto$905$113,01783 claims
Boehringer IngelheimJardiance$366$86,15595 claims
AstraZenecaFarxiga$790$56,64154 claims
Novo NordiskOzempic$508$56,55647 claims
Lilly USA, LLCMounjaro$18$28,54724 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$353$23,41327 claims
Sanofi-aventis U.S. LLCMultaq$49$10,15114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →